《美股業績》輝瑞(PFE.US)今年新冠疫苗及抗病毒口服藥銷售預測遜預期
輝瑞(PFE.US)第四季盈利按年增長3倍至33.93億美元,收入增長一倍至238.38億美元。公司預計今年新冠疫苗及抗病毒口服藥的銷售將超過540億美元,不及市場預期。
輝瑞預計今年抗病毒口服藥Paxlovid的銷售額將達到220億美元,低於市場預期的228.8億美元;但行政總裁Albert Bourla表示,Paxlovid最終銷售額可能比公司預期的要強勁的多,因目前的預測僅包括已經或即將簽署的合約。
Bourla續指,上述220億美元的預測僅佔今年準備生產的1.2億個療程的一小部分,目前公司正在與超過100個國家及地區就出售Paxlovid展開積極談判,如果需要公司有能力提供超過1.2億個療程。
另外,輝瑞預計今年新冠疫苗的銷量可能不會超過目前預測的320億美元,而這個預測亦低於市場預計的337.9億美元。
總體而言,輝瑞預計全年總銷售額爲980億至1,020億美元,亦低於市場預期的1,054.8億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.